Rhelion Life Sciences Corp. (CSE:RHEL)
Canada · Delayed Price · Currency is CAD 0.0300
-0.0025 (-7.69%)
Sep 18, 2026, 1:31 PM EST
Rhelion Life Sciences Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3.83 | 4.2 | 4.94 | 4.75 | 3.95 | 2.33 |
| 3.83 | 4.2 | 4.94 | 4.75 | 3.95 | 2.33 | |
Revenue Growth | -2.80% | -15.15% | 4.05% | 20.31% | 69.84% | 1995.96% |
Cost of Revenue | 2.22 | 2.6 | 3.03 | 2.73 | 2.24 | 1.71 |
Gross Profit | 1.61 | 1.59 | 1.91 | 2.02 | 1.71 | 0.62 |
Selling, General & Admin | 5.73 | 5.43 | 5.69 | 6.74 | 6 | 5.74 |
Research & Development | 0.1 | 0.02 | 0.02 | 0.05 | 0.31 | 0.75 |
Other Operating Expenses | - | - | -0.16 | - | -0.21 | 0.43 |
Operating Expenses | 6.22 | 6.02 | 6.12 | 8.21 | 6.66 | 10.13 |
Operating Income | -4.61 | -4.43 | -4.21 | -6.19 | -4.95 | -9.51 |
Interest Expense | -0.05 | -0.06 | -0.28 | -0.26 | -0.06 | -0.05 |
Interest & Investment Income | 0.21 | 0.26 | 0.49 | 0.53 | 0.21 | 0.06 |
Currency Exchange Gain (Loss) | -0 | -0 | -0.01 | -0.01 | -0.02 | -0.01 |
Other Non Operating Income (Expenses) | - | - | 0.23 | 0.01 | -0.08 | - |
EBT Excluding Unusual Items | -4.48 | -4.23 | -3.79 | -5.91 | -4.9 | -9.51 |
Gain (Loss) on Sale of Investments | -0.75 | -0.68 | -0.24 | 0.12 | -0.35 | -0.22 |
Gain (Loss) on Sale of Assets | -0.02 | -0.03 | 0 | 0.01 | - | - |
Asset Writedown | -2.15 | -2.15 | -0.53 | -2.03 | -0.44 | -5.94 |
Other Unusual Items | -0.08 | -0.08 | 0.14 | 0.04 | -0.26 | 0.73 |
Pretax Income | -7.49 | -7.17 | -4.42 | -7.77 | -5.96 | -14.94 |
Income Tax Expense | -0.3 | -0.33 | -0.11 | -0.06 | -0.16 | -0.25 |
Earnings From Continuing Operations | -7.18 | -6.84 | -4.31 | -7.71 | -5.8 | -14.7 |
Earnings From Discontinued Operations | -0.51 | - | - | - | - | - |
Net Income to Company | -7.69 | -6.84 | -4.31 | -7.71 | -5.8 | -14.7 |
Minority Interest in Earnings | 0.75 | 0.74 | 0.27 | 0.09 | 0.4 | 0.33 |
Net Income | -6.94 | -6.1 | -4.04 | -7.63 | -5.4 | -14.37 |
Net Income to Common | -6.94 | -6.1 | -4.04 | -7.63 | -5.4 | -14.37 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 451 | 417 | 401 | 395 | 373 | 351 |
Shares Outstanding (Diluted) | 451 | 417 | 401 | 395 | 373 | 351 |
Shares Change | 11.59% | 3.86% | 1.49% | 5.92% | 6.18% | 66.67% |
EPS (Basic) | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | -0.04 |
EPS (Diluted) | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | -0.04 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -2.92 | -2.56 | -2.01 | -3.92 | -6.45 | -5.28 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
Gross Margin | 42.06% | 37.92% | 38.69% | 42.52% | 43.21% | 26.56% |
Operating Margin | -120.36% | -105.56% | -85.15% | -130.20% | -125.40% | -408.88% |
Profit Margin | -181.28% | -145.45% | -81.75% | -160.51% | -136.67% | -617.78% |
Free Cash Flow Margin | -76.16% | -61.06% | -40.73% | -82.53% | -163.33% | -227.18% |
EBITDA | -4.33 | -4.15 | -3.53 | -5.44 | -4.47 | -9.04 |
EBITDA Margin | -113.09% | -98.80% | -71.35% | -114.48% | -113.07% | - |
D&A For EBITDA | 0.28 | 0.28 | 0.68 | 0.75 | 0.49 | 0.47 |
EBIT | -4.61 | -4.43 | -4.21 | -6.19 | -4.95 | -9.51 |
EBIT Margin | -120.36% | -105.55% | -85.15% | -130.20% | -125.40% | - |
Advertising Expenses | - | 0.12 | 0.21 | 0.33 | 0.28 | - |